63335-17-1

Upstream product

• 350-46-9 4-Fluoronitrobenzene 
• 124-68-5 2-Amino-2-methyl-1-propanol 

Downstream Products

• 860032-57-1 4-(2-amino-2-methyl-propoxy)-phenylamine 
• 860032-25-3 TD-4306 
• 860032-37-7 [4-(2-amino-ethyl)-phenyl]-[4-(2-amino-2-methyl-propoxy)-phenyl]-amine 
• 860032-33-3 5-[(R)-2-(2-{4-[4-(2-amino-2-methyl-propoxy)-phenylamino]-phenyl}-ethylamino)-1-(tert-butyl-dimethyl-silanyloxy)-ethyl]-8-benzyloxy-1H-quinolin-2-one 
• 860032-34-4 5-[(R)-2-(2-{4-[4-(2-amino-2-methyl-propoxy)-phenylamino]-phenyl}-ethylamino)-1-hydroxy-ethyl]-8-benzyloxy-1H-quinolin-2-one 

Relevant academic research and scientific papers

TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE

Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.

Discovery of TD-4306, a long-acting β2-agonist for the treatment of asthma and COPD

A multivalent approach focused on amine-based secondary binding groups was applied to the discovery of long-acting inhaled β2-agonists. Addition of amine moieties to the neutral secondary binding group of an existing β2-agonist serie

CINNAMATE SALTS OF A BETA-2 ADRENERGIC AGONIST

This invention relates to cinnamate salts of 5- [ (R) -2- (2-andlcub ; 4- [4- (2-amino-2-methyl-propoxy) -phenyl amino] -phenyl andrcub ; -ethylamino) -1 -hydroxy- ethyl] -8-hydroxy-lH-quinolin-2-one ,which may be depicted by the structural Formula (I).